Literature DB >> 29937179

HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes.

G S Kireeva1, G I Gafton2, K D Guseynov2, K Y Senchik2, O A Belyaeva2, V G Bespalov2, A V Panchenko2, M A Maydin2, A M Belyaev2.   

Abstract

A systematic review of the studies where HIPEC combined with cytoreductive surgery was used in patients with primary advanced ovarian cancer was performed to understand is there a role for this treatment modality not only in recurrent but in primary advanced ovarian cancer. The results are controversial but there is a strong trend for improvement of the long-term outcomes of patients with primary advanced ovarian cancer after HIPEC.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytoreductive surgery; HIPEC; Neoadjuvant chemotherapy; Primary advanced ovarian cancer

Mesh：

Year:  2018        PMID： 29937179     DOI： 10.1016/j.suronc.2018.05.006

Source DB:  PubMed          Journal:  Surg Oncol        ISSN： 0960-7404            Impact factor:   3.279


  6 in total

1.  Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.

Authors:  Kurinchi Gurusamy; Claire L Vale; Elena Pizzo; R Bhanot; Brian R Davidson; Tim Mould; Muntzer Mughal; Mark Saunders; Omer Aziz; Sarah O'Dwyer
Journal:  BMJ Open       Date:  2020-05-12       Impact factor: 2.692

2.  Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience.

Authors:  Fabio Carboni; Orietta Federici; Isabella Sperduti; Settimio Zazza; Domenico Sergi; Francesco Corona; Mario Valle
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

3.  Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.

Authors:  Manuel Gomes David; Naoual Bakrin; Julia Salleron; Marie Christine Kaminsky; Jean Marc Bereder; Jean Jacques Tuech; Kuno Lehmann; Sanket Mehta; Olivier Glehen; Frédéric Marchal
Journal:  BMC Surg       Date:  2022-01-07       Impact factor: 2.102

4.  Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients.

Authors:  Jue Zhang; Xin-Bao Li; Zhong-He Ji; Ru Ma; Wen-Pei Bai; Yan Li
Journal:  Biomed Res Int       Date:  2021-06-22       Impact factor: 3.411

Review 5.  Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer.

Authors:  Andrea Jewell; Megan McMahon; Dineo Khabele
Journal:  Cancers (Basel)       Date:  2018-09-01       Impact factor: 6.639

6.  Long term survival of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in advanced epithelial ovarian cancer.

Authors:  Jue Zhang; Xin-Bao Li; Ru Ma; Zhong-He Ji; Wenpei Bai; Yan Li
Journal:  Transl Cancer Res       Date:  2021-08       Impact factor: 1.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.